Participants:18–64 years · 65+ years
Substances:(3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione

Contact Research Centre

Follicular lymphoma

Not recruiting

Registered drugNo placebo

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Diabetic nephropathy

Not recruiting

Registered drug

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Empagliflozin

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Durvalumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Registered drugNo placebo

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Psoriasis

Not recruiting

Registered drug

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Brodalumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Amivantamab

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Registered drugNo placebo

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Lorlatinib

Contact Research Centre

Find therapies in clinical trials near you – page 14

198 trials match your criteria

Non-small cell lung cancer

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Breast cancer

Study on the Safety and Effectiveness of Vepdegestrant and PF-07220060 for Adults with ER+/HER2- Advanced or Metastatic Breast Cancer

Follicular lymphoma

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Diabetic nephropathy

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Breast cancer

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Non-small cell lung cancer

Study of Durvalumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Small cell lung cancer extensive stage

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Psoriasis

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Non-small cell lung cancer

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Breast cancer metastatic+2

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Non-small cell lung cancer

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Non-small cell lung cancer+2

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.